Search
Nabiximols
go.drugbank.com/drugs/DB14011InvestigationalIn contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body … Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site.
Categories: Cannabinoid Receptor AgonistsArimoclomol
go.drugbank.com/drugs/DB05025Approved[L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC).
Nitrazepam
go.drugbank.com/drugs/DB01595ApprovedA benzodiazepine derivative used as an anticonvulsant and hypnotic.
Rentiapril
go.drugbank.com/drugs/DB20567ExperimentalThe usage of the INN stem '-pril' in the name indicates that Rentiapril is a angiotensin-converting enzyme inhibitor. Rentiapril has a monoisotopic molecular weight of 313.04 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemDocosanol
go.drugbank.com/drugs/DB00632ApprovedDocosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.
Flumequine
go.drugbank.com/drugs/DB08972ApprovedWithdrawnFlumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
Ioflupane I-123
go.drugbank.com/drugs/DB08824ApprovedInvestigationalIoflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.
Etamivan
go.drugbank.com/drugs/DB08989ApprovedWithdrawnEtamivan (INN) or ethamivan (USAN) is marketed under the name Analepticon. Etamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.
Viper antivenom
go.drugbank.com/drugs/DB14114ApprovedInvestigationalANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation
Carboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigationalCarboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.